CL2021002145A1 - Uso terapéutico de relacorilant, un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada. - Google Patents

Uso terapéutico de relacorilant, un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada.

Info

Publication number
CL2021002145A1
CL2021002145A1 CL2021002145A CL2021002145A CL2021002145A1 CL 2021002145 A1 CL2021002145 A1 CL 2021002145A1 CL 2021002145 A CL2021002145 A CL 2021002145A CL 2021002145 A CL2021002145 A CL 2021002145A CL 2021002145 A1 CL2021002145 A1 CL 2021002145A1
Authority
CL
Chile
Prior art keywords
disorder
grm
relacorilant
azadecalin
fused heteroaryl
Prior art date
Application number
CL2021002145A
Other languages
English (en)
Inventor
Andreas Moraitis
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CL2021002145A1 publication Critical patent/CL2021002145A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan métodos y composiciones para el diagnóstico de un paciente que padece y para tratar a un paciente que padece un trastorno como hipercotisolemia, síndrome metabólico, prediabetes, diabetes, síndrome de Cushing, enfermedad de Cushing, hiperglucemia secundaria a hipercortisolemia, una enfermedad hepática, un trastorno cardíaco, hipertensión arterial, un trastorno de la coagulación sanguínea, un cáncer, un trastorno sicológico, aumento de peso, un trastorno del control de la glucosa, un trastorno óseo (por ejemplo, osteoporosis), hipogonadismo, pseudoacromegalia, tumores hipofisarios, hipercortisolismo funcional, tumores que segregan ACTH, neuropatía periférica, dislipidemia y otros trastornos. Los métodos y composiciones incluyen la administración de un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada (GRM). El GRM azadecalina heteroaril-cetona fusionada es relacorilant ((R)-(1-(4-fluorofenil)-6-((1-metil-1H-pirazol-4-il)sulfonil)-4,4a,5,6,7,8-hexahidro-1H-pirazolo[3,4-g]isoquinolin-4a-il)(4-(trifluorometil)piridin-2-il)metanona). En algunos casos, el GRM (por ejemplo, relacorilant) se administra por vía oral. En algunos casos, el GRM (por ejemplo, relacorilant) se administra por vía oral en ayunas.
CL2021002145A 2019-02-22 2021-08-13 Uso terapéutico de relacorilant, un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada. CL2021002145A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809327P 2019-02-22 2019-02-22
US201962814441P 2019-03-06 2019-03-06
US201962833517P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
CL2021002145A1 true CL2021002145A1 (es) 2022-01-28

Family

ID=72141382

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002145A CL2021002145A1 (es) 2019-02-22 2021-08-13 Uso terapéutico de relacorilant, un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada.

Country Status (14)

Country Link
US (4) US11058670B2 (es)
EP (1) EP3927345A4 (es)
JP (2) JP2022523376A (es)
KR (1) KR20210118971A (es)
CN (1) CN113490496A (es)
AU (1) AU2020226863B2 (es)
BR (1) BR112021015129A2 (es)
CA (1) CA3131263C (es)
CL (1) CL2021002145A1 (es)
IL (1) IL285771A (es)
MX (1) MX2021010135A (es)
SG (1) SG11202108964YA (es)
WO (1) WO2020172501A1 (es)
ZA (1) ZA202105633B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
NZ776354A (en) 2018-12-19 2023-03-31 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
MX2021007490A (es) * 2018-12-21 2021-08-05 Corcept Therapeutics Inc Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.
US11058670B2 (en) 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2021279006A1 (en) * 2020-05-27 2022-12-15 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
WO2023225282A1 (en) * 2022-05-20 2023-11-23 Corcept Therapeutics Incorporated Methods of treating cushing's syndrome and liver disorders, and of reducing liver toxicity of other drugs administered to a patient
WO2024077169A1 (en) * 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US20240197716A1 (en) * 2022-11-30 2024-06-20 Corcept Therapeutics Incorporated Treatments for cushing's syndrome that do not significantly affect cardiac rhythms

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (es) 1954-11-30 1957-04-11
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
EP0712402B1 (en) 1993-08-06 2002-04-10 Smithkline Beecham S.p.A. Hydroisoquinoline derivatives
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
ATE522503T1 (de) 1998-03-10 2011-09-15 Res Triangle Inst Neue opiate, herstellungsverfahren und verwendungen
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
BR0211365A (pt) 2001-07-23 2004-09-21 Corcept Therapeutics Inc Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica
EP1467730A4 (en) 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP2005535664A (ja) 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CN1874771A (zh) 2003-09-03 2006-12-06 惠氏公司 3－羟基－2－(羟甲基)－2－甲基丙酸的非晶态雷帕霉素42－酯及其包含相同化合物的药用组合物
ES2313296T3 (es) 2004-01-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina.
CA2557597A1 (en) 2004-02-26 2005-09-09 S. Stoney Simons Jr. A novel cofactor that modulates steroid receptor activities
US7928237B2 (en) 2004-03-09 2011-04-19 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
WO2006106052A1 (en) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
PL2757099T3 (pl) 2005-05-12 2018-02-28 Abbvie Bahamas Limited Promotory apoptozy
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2009058944A2 (en) 2007-11-01 2009-05-07 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
EP2217227B1 (en) 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US8598154B2 (en) * 2010-08-27 2013-12-03 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
BR122019026836B1 (pt) 2011-11-11 2021-02-23 Gilead Apollo, Llc composto, e, métodos de inibição de acc em uma amostra biológica e em uma planta
DK3111950T3 (da) 2012-02-24 2021-10-04 Univ Chicago Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3590517T3 (pl) * 2012-05-25 2021-09-20 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
MY180141A (en) 2013-11-25 2020-11-23 Corcept Therapeutics Inc Octahydro fused azadecalin glucocorticoid receptor modulators
CA2977591A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
JP6768789B2 (ja) * 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
US10980797B2 (en) 2016-03-01 2021-04-20 Corcept Therapeutics Incorporated Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
JP2020515563A (ja) 2017-03-31 2020-05-28 コーセプト セラピューティクス， インコーポレイテッド 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
US20180325891A1 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
MX2021007490A (es) * 2018-12-21 2021-08-05 Corcept Therapeutics Inc Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.
US11058670B2 (en) 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Also Published As

Publication number Publication date
SG11202108964YA (en) 2021-09-29
ZA202105633B (en) 2023-02-22
US20230346756A1 (en) 2023-11-02
CA3131263C (en) 2024-01-02
KR20210118971A (ko) 2021-10-01
EP3927345A4 (en) 2022-12-21
WO2020172501A1 (en) 2020-08-27
AU2020226863A1 (en) 2021-08-12
AU2020226863B2 (en) 2023-04-06
BR112021015129A2 (pt) 2021-09-28
US11058670B2 (en) 2021-07-13
JP2022523376A (ja) 2022-04-22
US20210338643A1 (en) 2021-11-04
US11684612B2 (en) 2023-06-27
EP3927345A1 (en) 2021-12-29
US20230131372A1 (en) 2023-04-27
US20200268723A1 (en) 2020-08-27
MX2021010135A (es) 2021-09-23
US11590113B2 (en) 2023-02-28
IL285771A (en) 2021-10-31
JP2024009951A (ja) 2024-01-23
CN113490496A (zh) 2021-10-08
CA3131263A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
CL2021002145A1 (es) Uso terapéutico de relacorilant, un modulador del receptor de glucocorticoide azadecalina heteroaril-cetona fusionada.
US11304932B2 (en) Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
Cutler et al. Four-week, double-blind, placebo-and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia
US8697662B2 (en) Methods for treating Kaposi sarcoma
Citrome Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy
Bello et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib
Xue et al. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164–driven angiogenesis, in part by blocking S6Kinase
US8703726B2 (en) Methods for treating prostate conditions
US20120157401A1 (en) Methods for treating neurofibromatosis
JP2021169498A (ja) ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター
Bertlich et al. Histaminergic H3-heteroreceptors as a potential mediator of betahistine-induced increase in cochlear blood flow
CN101980708A (zh) 作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物
Mbaki et al. Investigation of the role of 5‐HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat
JP2019506367A (ja) 疼痛を治療するためのｋｖ３チャネルのモジュレーター
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
Chen et al. Antihypertensive action of allantoin in animals
Mbaki et al. 5-HT2A receptor activation of the external urethral sphincter and 5-HT2C receptor inhibition of micturition: A study based on pharmacokinetics in the anaesthetized female rat
Pakkanen et al. Detomidine and the combination of detomidine and MK-467, a peripheral alpha-2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane
CL2021001528A1 (es) Formulaciones farmacéuticas que contienen relacorilant, un compuesto heteroaril-cetona azadecalina fusionada.
Kiesewetter et al. Ondansetron for diarrhea associated with neuroendocrine tumors
Rosenbaum et al. Psychedelics for psychological and existential distress in palliative and cancer care
Raedler Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia
JP2006523715A (ja) 新生物形成の治療のためのｃｏｘ−２阻害薬とアルキル化型抗新生物剤との組合せ医薬
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
CN110087653A (zh) 用于治疗肺高血压的组合疗法